Literature DB >> 8142312

Inhibition of the activity of 'basic' 5 alpha-reductase (type 1) detected in DU 145 cells and expressed in insect cells.

S Délos1, C Iehlé, P M Martin, J P Raynaud.   

Abstract

The purpose of this study was 2-fold: (1) to identify the 5 alpha-reductase (5 alpha-R) isozyme(s) present in DU 145 cells, a human cell-line of low androgen sensitivity derived from a cerebral metastasis of an epithelial prostate cancer; and (2) to compare the inhibitory potencies of three compounds on the 'basic' 5 alpha-R isozyme expressed in a baculovirus-directed insect cell system. Conversion of testosterone (T) into 5 alpha-dihydrotestosterone (DHT) in DU 145 cells was measured by HPLC coupled to a Flo-one HP radioactivity detector. DU 145 cells exhibited 5 alpha-R activity (21 pmol DHT/min/mg protein) at pH 7.4 which disappeared at pH 5.5 suggesting that, of the two genomically distinct human isozymes identified so far, type 1 5 alpha-R is expressed in DU 145 cells. This was confirmed by at least two observations: first, 5 alpha-R activity in DU 145 cells was inhibited with much higher potency by 4-MA than by finasteride which is known to be a very poor competitor of the 'basic' enzyme (IC50s = 2.8 +/- 0.2 and 264 +/- 55 nM, respectively). Second, only the type 1 5 alpha-R cDNA and not type 2 5 alpha-R cDNA hybridized with DU 145 RNA. A high potency differential was also recorded for the inhibition of 'basic' type 1 5 alpha-R expressed in a baculovirus-directed-insect cell system by these two compounds, 4-MA being considerably more active than finasteride (Ki = 8.4 +/- 2.3 and 330 +/- 9 nM, respectively). This inhibition was competitive. On the other hand, inhibition by an n-hexane lipid/sterol extract of Serenoa repens (LSESr) was non-competitive and, when expressed in terms of recommended therapeutic doses, was 3-fold greater for LSESr than for finasteride. These studies suggest that LSESr might exert a regulatory inhibitory activity due to its specific lipid/sterol composition.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8142312     DOI: 10.1016/0960-0760(94)90074-4

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  13 in total

1.  The potential for prostate cancer chemoprevention.

Authors:  Otis W Brawley
Journal:  Rev Urol       Date:  2002

Review 2.  Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia.

Authors:  G L Plosker; R N Brogden
Journal:  Drugs Aging       Date:  1996-11       Impact factor: 3.923

3.  Distribution study of radioactivity in rats after oral administration of the lipido/sterolic extract of Serenoa repens (Permixon) supplemented with [1-14C]-lauric acid, [1-14C]-oleic acid or [4-14C]-beta-sitosterol.

Authors:  G Chevalier; P Benard; H Cousse; T Bengone
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Jan-Mar       Impact factor: 2.441

4.  Preventing progression in men with mild symptoms of benign prostatic hyperplasia: a potential role for phytotherapy.

Authors:  Yan Kit Fong; Sibylle Marihart; Mike Harik; Bob Djavan
Journal:  Rev Urol       Date:  2004

Review 5.  Pharmacological effects of saw palmetto extract in the lower urinary tract.

Authors:  Mayumi Suzuki; Yoshihiko Ito; Tomomi Fujino; Masayuki Abe; Keizo Umegaki; Satomi Onoue; Hiroshi Noguchi; Shizuo Yamada
Journal:  Acta Pharmacol Sin       Date:  2009-03       Impact factor: 6.150

6.  Characterization of rat 5alpha-reductases type 1 and type 2 expressed in Saccharomyces cerevisiae.

Authors:  A Poletti; F Celotti; M Motta; L Martini
Journal:  Biochem J       Date:  1996-03-15       Impact factor: 3.857

7.  Strategies for prostate cancer prevention: Review of the literature.

Authors:  H Krishna Moorthy; P Venugopal
Journal:  Indian J Urol       Date:  2008-07

8.  Modulating testosterone pathway: a new strategy to tackle male skin aging?

Authors:  Philippe Bernard; Thomas Scior; Quoc Tuan Do
Journal:  Clin Interv Aging       Date:  2012-09-13       Impact factor: 4.458

Review 9.  Phytotherapy for benign prostatic hyperplasia.

Authors:  Glenn S Gerber
Journal:  Curr Urol Rep       Date:  2002-08       Impact factor: 2.862

10.  Inhibition of inflammatory gene expression in keratinocytes using a composition containing carnitine, thioctic Acid and saw palmetto extract.

Authors:  Sridar Chittur; Brian Parr; Geno Marcovici
Journal:  Evid Based Complement Alternat Med       Date:  2011-06-08       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.